Drospirenone/estetrol monohydrate (Drovelis®). HTA ID: 22073

Assessment Status Rapid Review Complete
HTA ID 22073
Drug Drospirenone/estetrol monohydrate
Brand Drovelis®
Indication Drospirenone/estetrol monohydrate is indicated for oral contraception.
Assessment Process
Rapid review commissioned 07/12/2022
Rapid review completed 23/01/2023
Rapid review outcome A full HTA is not recommended. The NCPE recommends that drospirenone/estetrol monohydrate not be considered for reimbursement at the submitted price*.

*This recommendation should be considered while also having regard to the criteria specified in the Health (Pricing and Supply of Medical Goods) Act 2013.

The HSE has approved reimbursement; June 2023